Comparison of brolucizumab and aflibercept for treating DME - Modern Retina

A study found brolucizumab non-inferior to aflibercept in treating DME, with superior anatomic outcomes. Both drugs showed similar adverse event rates. The meta-analysis underscores the need for further trials to assess safety outcomes for brolucizumab as a DME treatment alternative.